In June, the FDA approved once-weekly injectable semaglutide 2.4 mg (Wegovy, Novo Nordisk), a GLP-1 receptor agonist, for chronic weight management in adults with obesity or with overweight and at least one weight-related condition
Eating disorder, low protein intake
Self-administering retatrutide outside a clinical trial carries serious risks including infection, product impurity, incorrect dosing, and lack of pharmacovigilance protection
You got to see what works best for you, and that's why I seek out other people, people like myself, other physicians, other people who have experience saying, "Hey, we'll help you guide you in this." That's where the magic happens
Neurobiol Dis 155:105370
This is why two people taking the exact same milligram dose can inject very different volumes, because their vials have different concentrations